Exposure (and Dose) Response Analyses, including pharmacokinetic and pharmacodynamics analyses, guide critical decisions in drug development. Cytel's expert Quantitative Pharmacology and Pharmacometrics group delivers high quality solutions to help our customers get those decisions right.
Phase I Biometric Services Including Pharmacokinetic (PK) Analyses
Non Compartmental Analysis (NCA)
PK Tables Listings and Figures
PK section of Clinical Study Report
SAS.XPT (transport) Files
Statistical analysis and reporting for first in human studies:
Single Ascending Dose (SAD) Studies
Multiple Ascending Dose (MAD) Studies
SAD/ MAD studies
Drug-Drug Interaction Studies
Food effect- drug/ food interaction studies
Bioavailability and Bioequivalence Studies
Population PK modeling including identifying significant covariates of exposure
Exposure-response population modeling and simulation of safety/ and or efficacy endpoints
Nonlinear modeling of biomarker to clinical endpoint relationships
Risk-benefit assessments and identification of therapeutic index
Clinical Database Development
Source Database (SDB)
Outcomes Database (ODB)
Using a refined process and proprietary software PubCode , we can efficiently extract summary level clinical trial outcome data along with detailed information on treatment, patient population, and trial characteristics.
Need More Information? Just Ask.
Click the button below to directly contact the supplier. Use it to: